Johnson & Johnson shares positive late-stage results for Tremfya in psoriatic arthritis - PMLiVE The inflammatory condition affects approximately 30% of psoriasis patients

#immunology #rheumatology #InnovativeMedicine #jointhealth #JohnsonandJohnson #JandJ #JnJ #Tremfya #guselkumab #psoriaticarthritis #PsA #APEXtrial #activePsA #IL23blocker #pathogenesis #inflammatorydiseases #CD64receptor #CD64receptorbinder #IL23inhibitor #IL23treatment
pmlive.com/pharma_news/...